CEL — Celadon Pharmaceuticals Balance Sheet
0.000.00%
- £4.47m
- £9.26m
- £0.08m
Annual balance sheet for Celadon Pharmaceuticals, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2019 August 31st | 2020 August 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 5.65 | 5.49 | 3.82 | 5.06 | 1.26 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.016 | 0.01 | 0.104 | 1.06 | 0.841 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 5.66 | 5.5 | 4.09 | 6.33 | 2.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | — | — | 3.31 | 6.28 | 6.17 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 5.66 | 5.5 | 8.76 | 13.3 | 9.22 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 0.021 | 0.03 | 8.58 | 1.2 | 0.955 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.033 | 0.042 | 12.9 | 5.58 | 6.06 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 5.63 | 5.46 | -4.14 | 7.67 | 3.16 |
Total Liabilities & Shareholders' Equity | 5.66 | 5.5 | 8.76 | 13.3 | 9.22 |
Total Common Shares Outstanding |